^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Retinoic acid receptor agonist

    Related drugs:
    4d
    Auricular Acupressure Combined With Adapalene for the Treatment of Acne Vulgaris (clinicaltrials.gov)
    P=N/A, N=64, Completed, University of Medicine and Pharmacy at Ho Chi Minh City
    New trial
    6d
    Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne. (clinicaltrials.gov)
    P=N/A, N=102, Active, not recruiting, Pierre Fabre Dermo Cosmetique
    New trial
    18d
    Extended cycles of anti-GD2 antibody dinutuximab beta treatment combined with chemotherapy in patients with relapsed or refractory neuroblastoma: A retrospective study. (PubMed, Oncol Lett)
    In this single-center retrospective study, children with a median age 5.1 years (range, 2.0-11.1 years) with R/R HR-NB who were treated with >5 cycles of dinutuximab beta (10 mg/m2/day for 10-days per 35-day cycle), granulocyte-macrophage colony-stimulating factor (GM-CSF) and isotretinoin, plus chemotherapy, were included. No immune-related deaths occurred. Overall, cycles beyond the standard 5 cycles of dinutuximab beta with chemoimmunotherapy were effective and tolerable in pediatric patients with R/R HR-NB, demonstrating improved response and survival outcomes.
    Retrospective data • Journal
    |
    CSF2 (Colony stimulating factor 2)
    |
    Qarziba (dinutuximab beta)
    20d
    Effects of Isotretinoin on Smell (clinicaltrials.gov)
    P=N/A, N=54, Recruiting, Uşak University
    New trial
    21d
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Dwight Owen | Trial primary completion date: Jan 2026 --> Sep 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    27d
    Experience With Topical Acne Treatment (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, Wake Forest University Health Sciences | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2026 --> Jun 2025
    Enrollment closed • Trial primary completion date
    30d
    Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer (clinicaltrials.gov)
    P2, N=76, Terminated, Mario Negri Institute for Pharmacological Research | N=112 --> 76 | Trial completion date: Sep 2024 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Jan 2025; Low enrolment rate
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    anastrozole • Vesanoid (tretinoin)
    1m
    Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P2, N=151, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
    |
    Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide
    1m
    SG05 The use of oral methotrexate in a case of Ferguson-Smith syndrome. (PubMed, Br J Dermatol)
    Despite 3 years of acitretin therapy, surgical excisions, imiquimod and repeated cryotherapy, the lesions remained poorly controlled. This case, along with her sister's experience, highlights oral methotrexate as a potential therapeutic option for refractory cases. Further studies are needed to explore its role in the management of this challenging condition.
    Journal
    |
    TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    methotrexate • Zyclara (imiquimod)
    1m
    A Red Lobulated Facial Mass: A Clinicopathological Challenge. (PubMed, Int J Dermatol)
    The condition was refractory to initial methotrexate and isotretinoin therapy. We report a rare and clinically challenging case of RDD diagnosed with the aid of histopathology and immunohistochemistry. Additionally, we emphasize the role of a combined approach of serial surgical excisions and systemic dapsone therapy.
    Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    methotrexate
    2ms
    Laser Therapy in the Isotretinoin-Induced Sacroiliitis (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Uşak University
    New trial
    2ms
    Exercise Therapy for Isotretinoin Users (clinicaltrials.gov)
    P=N/A, N=160, Recruiting, Uşak University | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events